Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-031/00
G01N-033/53
출원번호
US-0349170
(2012-01-12)
등록번호
US-8232068
(2012-07-31)
발명자
/ 주소
Albitar, Maher
Keating, Michael J.
Manshouri, Taghi
출원인 / 주소
Board of Regents, The University of Texas System
대리인 / 주소
Fulbright & Jaworski L.L.P.
인용정보
피인용 횟수 :
4인용 특허 :
15
초록▼
The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone a
The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
대표청구항▼
1. A method of determining tumor mass comprising: contacting a patient sample with a first anti-CD20 antibody, wherein the first anti-CD20 antibody captures circulating cell-free CD20 in the patient sample;contacting the captured circulating cell-free CD20 with a second anti-CD20 antibody; andmeasur
1. A method of determining tumor mass comprising: contacting a patient sample with a first anti-CD20 antibody, wherein the first anti-CD20 antibody captures circulating cell-free CD20 in the patient sample;contacting the captured circulating cell-free CD20 with a second anti-CD20 antibody; andmeasuring the level of the second anti-CD20 antibody, wherein the level of the second anti-CD20 antibody correlates with tumor mass. 2. The method of claim 1, wherein the patient sample is selected from the group consisting of serum, cell lysate and plasma. 3. The method of claim 1 wherein the first antibody or the second anti-CD20 antibody is Rituximab. 4. The method of claim 1 wherein the second anti-CD20 antibody is labeled. 5. The method of claim 4, wherein the labeled second anti-CD20 antibody is Rituximab. 6. The method of claim 1, wherein the tumor is melanoma, non-small cell lung, small-cell lung, lung hepatocarcinoma, retinoblastoma, astrocytoma, gliobastoma, gum, tongue, leukemia, neuroblastoma, head, neck, breast, pancreatic, prostate, renal, bone, testicular, ovarian, mesothelioma, cervical, gastrointestinal, lymphoma, brain, colon, or bladder. 7. The method of claim 1, wherein the tumor is a B-cell tumor. 8. The method of claim 7, wherein the B-cell tumor is chronic lymphocytic leukemia. 9. A method of measuring circulating cell-free CD20 comprising: contacting a sample with a first anti-CD20 antibody, wherein the first anti-CD20 antibody captures circulating cell-free CD20 in the sample;contacting the captured circulating cell-free CD20 with a second anti-CD20 antibody; andmeasuring the level of the second anti-CD20 antibody, wherein the level of the second anti-CD20 antibody correlates with the level of circulating cell-free CD20. 10. The method of claim 9, wherein the sample is selected from the group consisting of serum, cell lysate and plasma. 11. The method of claim 9 wherein the first antibody or the second anti-CD20 antibody is Rituximab. 12. The method of claim 9 wherein the second anti-CD20 antibody is labeled. 13. The method of claim 12, wherein the labeled second anti-CD20 antibody is Rituximab.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (15)
Miller Richard A. (8 Ohlone Portola Valley CA 94025), Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies.
Groffen John H. (Los Angeles CA) Heisterkamp Nora C. (Los Angeles CA) Hoeve Johanna Ten (Los Angeles CA), Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein.
Robinson Grenville Arthur,GBX ; Attridge John Worthington,GBX ; Deacon Julie Karen,GBX ; Daniels Phelim Brinley,GBX ; Love Colin Andrew,GBX ; Thomson Aileen Margaret,GBX, Method of assay having calibration within the assay.
Morton Donald L. (15054 Corona del Mar Pacific Palisades CA 90272) Gupta Rishab K. (7118 Costello Ave. Van Nuys CA 91405) Euhus David M. (7038 Ramsgate Pl. Los Angeles CA 90045), Method of detection of urinary tumor associated antigen.
Rittershaus Charles W. (Malden MA) Tian Wei-Tao (Allston MA) Kung Patrick C. (Lexington MA), Therapeutic and diagnostic methods using leukocyte surface antigens.
Anderson Darrell R. ; Hanna Nabil ; Leonard John E. ; Newman Roland A. ; Reff Mitchell E. ; Rastetter William H., Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.